[en] Recent clinical observations and experimental studies of our group indicate that macrophage migration inhibitory factor (MIF) may contribute to tumor progression in head and neck squamous cell carcinomas (HNSCC). The present study was undertaken to examine the effects of the irreversible MIF inhibitor 4-iodo-6-phenylpyrimidine (4-IPP) on proliferation and invasiveness of the squamous carcinoma cell line SCCVII. Cell counting, crystal violet assay and flow cytometry were used to analyze the effects of 4-IPP on SCCVII cell growth. The impact of 4-IPP on cell invasiveness was assessed by Boyden chamber assay. Knockdown of the MIF receptor CD74 was achieved by transduction with lentiviral vectors encoding anti-CD74 shRNAs. As shown by immunofluorescence staining, SCCVII cells express both MIF and CD74. Decreased MIF immunoreactivity as a result of exposure to 4-IPP suggested a covalent modification of the cytokine. 4-IPP inhibited SCCVII cell proliferation and invasiveness. Moreover, the cytostatic effect of 4-IPP was enhanced by CD74 knockdown. The inhibitory effects of 4-IPP on cell proliferation and invasiveness strongly suggest that MIF is involved in proliferative activity and invasive properties of squamous carcinoma cells. In conclusion, MIF inhibition may open possibilities for target-directed treatment of head and neck squamous cell carcinoma
Disciplines :
Immunology & infectious disease
Author, co-author :
Kindt, Nadège ; Université de Mons > Faculté de Médecine et de Pharmacie > Histologie
Laurent, Guy ; Université de Mons > Faculté de Médecine et de Pharmacie > Histologie
Nonclercq, Denis ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Histologie
Journé, Fabrice
Ghanem, Ghanem
Duvillier, Hugues
Gabius, Hans-Joachim
Lechien, Jérome ; Université de Mons > Faculté de Psychologie et des Sciences de l'Education > Métrologie et Sciences du langage
Saussez, Sven ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale
Language :
English
Title :
Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells
Publication date :
12 January 2013
Journal title :
International Journal of Oncology
ISSN :
1019-6439
Publisher :
Demetrios A. Spandidos Ed. & Pub., Greece
Volume :
43
Issue :
1
Pages :
185-193
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M112 - Anatomie humaine et Oncologie expérimentale M118 - Histologie
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC and David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 86: 7522-7526, 1989. (Pubitemid 19254488)
Sugimoto H, Suzuki M, Nakagawa A, Tanaka I and Nishihira J: Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 A resolution. FEBS Lett 389: 145-148, 1996. (Pubitemid 26226488)
Sun HW, Bernhagen J, Bucala R and Lolis E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 93: 5191-5196, 1996.
Kato Y, Muto T, Tomura T, Tsumura H, Watarai H, Mikayama T, Ishizaka K and Kuroki R: The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Proc Natl Acad Sci USA 93: 3007-3010, 1996. (Pubitemid 26116249)
Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K and Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1: 781-788, 1995. (Pubitemid 3013085)
Flaster H, Bernhagen J, Calandra T and Bucala R: The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 21: 1267-1280, 2007. (Pubitemid 46984737)
Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, Bucala R and Donnelly SC: Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 101: 2869-2874, 1998. (Pubitemid 28294596)
de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK and Terhorst C: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2: 1061-1066, 2001. (Pubitemid 33069502)
Morand EF, Leech M, Weedon H, Metz C, Bucala R and Smith MD: Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41: 558-562, 2002. (Pubitemid 34567187)
Foote A, Briganti EM, Kipen Y, Santos L, Leech M and Morand EF: Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31: 268-273, 2004. (Pubitemid 38160747)
Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW and Griffiths CE: Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123: 484-487, 2004. (Pubitemid 39095618)
Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR and Rodriguez-Sosa M: Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J 24: 2583-2590, 2010.
Chesney J, Metz C, Bacher M, Peng T, Meinhardt A and Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181-191, 1999. (Pubitemid 29252666)
Zeng F-Y, Weiser WY, Kratzin H, Stahl B, Karas M and Gabius HJ: The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor? Arch Biochem Biophys 303: 74-80, 1993. (Pubitemid 23212661)
Zeng FY, Gerke V and Gabius HJ: Characterization of the macrophage migration inhibitory factor-binding site of sarcolectin and its relationship to human serum albumin. Biochem Biophys Res Commun 200: 89-94, 1994. (Pubitemid 24183577)
Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng FY and Gabius H-J: Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer 30A: 653-657, 1994. (Pubitemid 24164253)
Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48: 448-452, 1996. (Pubitemid 26317487)
He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55: 797-802, 2006. (Pubitemid 43764549)
Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H and Balkwill FR: Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cell Ther 6: 1993-2002, 2007. (Pubitemid 47052489)
He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR and Al-Abed Y: Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 15: 1-10, 2009.
Krockenberger M, Engel JB, Kolb J, Dombrowsky Y, Häusler SF, Kohrenhagen N, Dietl J, Wischhusen J and Honig A: Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 136: 651-657, 2010.
Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius H-J and Saussez S: Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res 32: 4499-4505, 2012.
Kindt N, Preillon J, Kaltner H, Gabius H-J, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G and Saussez S: Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 139: 727-737, 2013.
Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ and Saussez S: Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 30: 3313-3319, 2010.
Cournia Z, Leng L, Gandavadi S, Du X, Bucala R and Jorgensen WL: Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem 52: 416-424, 2009.
Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO and Mitchell RA: A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 68: 7253-7257, 2008.
Khurana D, Martin EA, Kasperbauer JL, O'Malley BW Jr, Salomao DR, Chen L and Strome SE: Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 23: 899-906, 2001. (Pubitemid 32862295)
Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G and Body JJ: Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br J Cancer 91: 1703-1710, 2004. (Pubitemid 39546144)
Baron N, Deuster O, Noelker C, Stüer C, Strik H, Schaller C, Dodel R, Meyer B and Bacher M: Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res 89: 711-717, 2011.
Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ and Tracey KJ: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280: 36541-36544, 2005. (Pubitemid 41587728)
Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R and Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177: 8730-8739, 2006. (Pubitemid 44893839)
McClelland M, Zhao L, Carskadon S and Arenberg D: Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 174: 638-646, 2009.
Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, Nickel W, Kavathas PB, Bernhagen J and Bucala R: The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 182: 6896-6906, 2009.
Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R and Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688-703, 2006. (Pubitemid 43113299)
Bifulco C, McDaniel K, Leng L and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 14: 3790-3801, 2008.
Du W, Wright BM, Li X, Finke J, Rini BI, Zhou M, He H, Lal P and Welford SM: Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene 32: 1469-1474, 2013.
Liu L, Ji C, Chen J, Li Y, Fu X, Xie Y, Gu S and Mao Y: A global genomic view of MIF knockdown-mediated cell cycle arrest. Cell Cycle 7: 1678-1692, 2008. (Pubitemid 351881336)
Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 282: 29910-29918, 2007. (Pubitemid 350035289)
Lee CY, Su MJ, Huang CY, Chen MY, Hsu HC, Lin CY and Tang CH: Macrophage migration inhibitory factor increases cell motility and up-regulates αvβ3 integrin in human chondrosarcoma cells. J Cell Biochem 113: 1590-1598, 2012.
